{"id":50152,"date":"2022-10-27T12:01:48","date_gmt":"2022-10-27T10:01:48","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/"},"modified":"2022-10-27T12:01:48","modified_gmt":"2022-10-27T10:01:48","slug":"boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/","title":{"rendered":"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials"},"content":{"rendered":"
\n

\nCollaboration Includes Industry-Leading Technologies and Decentralized Clinical Trial Capabilities to Increase Study Efficiency and Patient Engagement<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–Medidata, a Dassault Syst\u00e8mes company, and Boehringer Ingelheim today announced a five-year renewal of their collaboration in the wider area of electronic data capture. The new agreement extends the use of Rave EDC for Boehringer Ingelheim’s clinical trials worldwide and includes myMedidata, Medidata\u2019s suite of innovative patient-facing technologies focused on enhancing patient centricity and diversity in decentralized clinical trials (DCTs).\n<\/p>\n

<\/a><\/p>\n

\nThe agreement adds to Boehringer Ingelheim\u2019s focus on engaging patients in a meaningful way by providing Medidata\u2019s scalable patient-centered capabilities. This includes the myMedidata patient portal, a single-destination web-based platform, which provides access to electronic consent, electronic Clinical Outcome Assessment (eCOA), and myMedidata LIVE video investigator\/patient visits.\n<\/p>\n

\n\u201cAs industry leaders, Boehringer Ingelheim and Medidata have a responsibility to innovate for the benefit of patients,\u201d said Anthony Costello, CEO Patient Cloud at Medidata. \u201cBoehringer Ingelheim\u2019s global reach across therapeutic areas is a perfect match for the scalable capabilities of myMedidata and the rest of the Medidata Clinical Cloud platform. Together, we will be able to quickly improve access and diversity of participation in a wide range of clinical programs.\u201d\n<\/p>\n

\nThe Medidata Decentralized Clinical Trials Program \u2013 the industry\u2019s only scalable, end-to-end offering \u2013 is helping to revolutionize how individuals provide data, how drugs are shipped to patients, and how clinical trial data are managed and monitored. Most importantly, these remote technologies create opportunities to improve patient access, inclusion, and engagement across geographies, and improve patient diversity in clinical trials.\n<\/p>\n

\nBoehringer Ingelheim has built on Medidata technologies, including Rave EDC (electronic data capture), Coder, TSDV (targeted source data verification), and Safety Gateway. Boehringer Ingelheim is also exploring Medidata AI Intelligent Trials to provide advanced analytics to improve the speed, success, and quality of clinical trials, and is benefitting from Medidata Rave Imaging technology via services contracted with the company\u2019s imaging suppliers.\n<\/p>\n

\nMedidata is a wholly owned subsidiary of Dassault Syst\u00e8mes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.\n<\/p>\n

\nAbout Medidata<\/b>\n<\/p>\n

\nMedidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world’s most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Syst\u00e8mes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com<\/a> and follow us @Medidata<\/a>.\n<\/p>\n

\nAbout Dassault Syst\u00e8mes<\/b>\n<\/p>\n

\nDassault Syst\u00e8mes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Syst\u00e8mes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com<\/a>\n<\/p>\n

\n3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Syst\u00e8mes, a French \u201csoci\u00e9t\u00e9 europ\u00e9enne\u201d (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and\/or other countries.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nTom Paolella
\n
Senior Director, Corporate Communications & Affairs
\n
+1-848-203-7596
\n
thomas.paolella@3ds.com<\/a>\n<\/p>\n

\nPaul Oestreicher
\n
External Communications Director
\n
+1-917-522-4692
\n
paul.oestreicher@3ds.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Collaboration Includes Industry-Leading Technologies and Decentralized Clinical Trial Capabilities to Increase Study Efficiency and Patient Engagement NEW YORK–(BUSINESS WIRE)–Medidata, a Dassault Syst\u00e8mes company, and Boehringer Ingelheim today announced a five-year renewal of their collaboration in the wider area of electronic data capture. The new agreement extends the use of Rave EDC for Boehringer Ingelheim’s clinical … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50152","6":"format-standard","7":"category-industry"},"yoast_head":"\nBoehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Collaboration Includes Industry-Leading Technologies and Decentralized Clinical Trial Capabilities to Increase Study Efficiency and Patient Engagement NEW YORK–(BUSINESS WIRE)–Medidata, a Dassault Syst\u00e8mes company, and Boehringer Ingelheim today announced a five-year renewal of their collaboration in the wider area of electronic data capture. The new agreement extends the use of Rave EDC for Boehringer Ingelheim’s clinical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T10:01:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221027005028\/en\/1613443\/21\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials\",\"datePublished\":\"2022-10-27T10:01:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/\"},\"wordCount\":665,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221027005028\\\/en\\\/1613443\\\/21\\\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/\",\"name\":\"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221027005028\\\/en\\\/1613443\\\/21\\\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg\",\"datePublished\":\"2022-10-27T10:01:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221027005028\\\/en\\\/1613443\\\/21\\\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221027005028\\\/en\\\/1613443\\\/21\\\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials - Pharma Trend","og_description":"Collaboration Includes Industry-Leading Technologies and Decentralized Clinical Trial Capabilities to Increase Study Efficiency and Patient Engagement NEW YORK–(BUSINESS WIRE)–Medidata, a Dassault Syst\u00e8mes company, and Boehringer Ingelheim today announced a five-year renewal of their collaboration in the wider area of electronic data capture. The new agreement extends the use of Rave EDC for Boehringer Ingelheim’s clinical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-27T10:01:48+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221027005028\/en\/1613443\/21\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials","datePublished":"2022-10-27T10:01:48+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/"},"wordCount":665,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221027005028\/en\/1613443\/21\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/","url":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/","name":"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221027005028\/en\/1613443\/21\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg","datePublished":"2022-10-27T10:01:48+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221027005028\/en\/1613443\/21\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221027005028\/en\/1613443\/21\/3DS_MEDIDATA_Logotype_RGB_PRIMARY.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-extends-the-use-of-medidata-rave-for-electronic-data-capture-in-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50152"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50152\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}